[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
January 3, 2001

New Combination Drug for HIV

Author Affiliations

Not Available

Not Available

JAMA. 2001;285(1):34. doi:10.1001/jama.285.1.34-JFD00011-2-1

The FDA has approved Trizivir (Glaxo Wellcome, Research Triangle Park, NC), alone or in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and adolescents. Trizivir is a combination of three synthetic nucleoside analogs previously approved by the FDA: abacavir sulfate (Ziagen), lamivudine (Epivir), and zidovudine (Retrovir). One Trizivir tablet is bioequivalent to one tablet each of Ziagen (300 mg), Epivir (150 mg), and Retrovir (300 mg). As a fixed-dosage tablet, Trizivir is not recommended for treatment of patients who weigh less than 90 lb.

First Page Preview View Large
First page PDF preview
First page PDF preview